Chongqing Lummy Pharmaceutical announced that the company recently received the "Drug Supplementary Application Approval Notice" for Cefepime Hydrochloride and Tazobactam Sodium for Injection issued by the National Medical Products Administration. This drug is a third-generation oral cephalosporin antibiotic used to treat infections caused by various sensitive bacteria.
莱美药业：头孢泊肟酯干混悬剂获药品补充申请批准
Chongqing Lummy Pharmaceutical: Cefepime Hydrochloride and Tazobactam Sodium for Injection obtains pharmaceutical supplementary application approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated